Bowel Disease
20
4
5
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.0%
1 terminated out of 20 trials
90.9%
+4.4% vs benchmark
25%
5 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (20)
Does the Common Practice of Adding Diluted Epinephrine in Tranverse Abdominal Plan Block to Ropivacaine Significantly Decrease the Peak Systemic Resorption of Ropivacaine?
Development of New Diagnostic Tools in Capsule Endoscopy
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
Exploratory Study of Rectal Mucus for Diagnosing Disease
The Effects Of Probiotics On Stress Among Healthy Adults From Umm Al-Qura University At Makkah
Deep Learning in Classifying Bowel Obstruction Radiographs
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
Evaluation of Blood Platelet Indices,Platelet Aggregation in the Activity of IBD Patients on Biological Treatment
The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery
Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
Plenvu 1 - Questionnaire Study Exploring Patients Preference in Bowel Preparation Timings for Morning Colonoscopy
Picoprep Split-dose Before Colonoscopy in Children
IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population
Study of NPO-13 During Colonoscopy
Biopotentials for Clinician Satisfaction With Sedation in Colonoscopy
Mindfulness Therapy in Inflammatory Bowel Disease
Comparison of Low Volume PEG-Asc and Lower Volume PEG-Asc With Bisacodyl